Can the further clinical development of bevirimat be justified?

AIDS

Volumn 24, Issue 5, 2010, Pages 773-774

  Wainberg, Mark A ^a   Albert, Jan ^b  

^a MCGILL UNIVERSITY   (Canada)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Bevirimat; Protease inhibitor resistance

Indexed keywords

BEVIRIMAT; ENFUVIRTIDE; GAG PROTEIN; INTEGRASE INHIBITOR; INTEGRASE STRAND TRANSFER INHIBITOR; MARAVIROC; PROTEIN P25; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL RESISTANCE; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENCY; DRUG SENSITIVITY; GENE MUTATION; GENETIC SCREENING; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NOTE; PRIORITY JOURNAL; PROTEIN SECRETION; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE CULTURE; TREATMENT FAILURE; VIRUS ISOLATION; VIRUS RESISTANCE; VIRUS STRAIN; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; DRUG APPROVAL; DRUG DESIGN; DRUG RESISTANCE, VIRAL; HUMANS; SUCCINATES; TRITERPENES;

EID: 77949416754     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328331c83b     Document Type: Note

References (9)

1. Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, Doto J, et al. Phase I and II study of the safety, virologic effect, and pharmacokinetics/ pharmacodynamics of single-dose 3-O-(3,3-dimethylsuccinyl) betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother 2007; 51:3574-3581.
2. Zhou J, Huang L, Hachey DL, Chen CH, Aiken C. Inhibition of HIV-1 maturation via drug association with the viral Gag protein in immature HIV-1 particles. J Biol Chem 2005; 280:42149-42155.
3. Zhou J, Chen CH, Aiken C.Human immunodeficiency virus type 1 resistance to the small molecule maturation inhibitor 3-O-(3,3-dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino acid substitutions at the CA-SP1 cleavage site in Gag. J Virol 2006; 80:12095-12101.
4. Salzwedel K, Martin DE, Sakalian M. Maturation inhibitors: a new therapeutic class targets the virus structure. AIDS Rev 2007; 9:162-172.
5. Malet I, Wirden M, Derache A, Simon A, Katlama C, Calvez V, Marcelin AG. Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients. AIDS 2007; 21:871-873.
6. Nijhuis M, van Maarseveen NM, Lastere S, Schipper P, Coakley E, Glass B, et al. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med 2007; 4:e36.
7. Verheyen J, Verhofstede C, Knops E, Vandekerckhove L, Fun A, Brunen D, et al. High prevalence of bevirimat resistance mutations in PI resistant HIV isolates. AIDS 2010; 24:669-673.
8. th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2009; Montreal, Canada.
9. Mart́inez-Cajas JL, Pant-Pai N, Klein MB, Wainberg MA. Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence. AIDS Rev 2008; 10:212-223.